معرفی
Huidong Shi serves as Professor in the Department of Biochemistry and Molecular Biology and Georgia Cancer Center at Augusta University's Medical College of Georgia. His dual appointments reflect his interdisciplinary work bridging basic science and oncology research.
Dr. Shi's research centers on epigenomic regulation in cancer, with three primary thrusts:
- Chronic Lymphocytic Leukemia (CLL): Pioneering DNA methylation profiling to identify molecular subtypes and super-enhancer-driven oncogenes, while investigating T-cell dysfunction mechanisms
- Spliceosome Targeting: Developing sudemycin D6 as a therapeutic for CLL through RNA splicing modulation and synergy with established drugs like ibrutinib
- Triple Negative Breast Cancer (TNBC): Studying IDO1 promoter hypomethylation as a unique biomarker and therapeutic target for immunotherapy resistance
His laboratory leverages single-cell genomics, epigenomics, and bioinformatic approaches to dissect transcriptional regulation in cancer immunotherapy and tumor microenvironments. Current work includes developing spliceosome modulators in collaboration with pharmaceutical startups and validating IDO1 methylation as a clinical biomarker.
Award Highlights:
- Georgia Cancer Coalition Distinguished Scholar
Dr. Shi actively mentors graduate students and postdoctoral fellows while serving on the Georgia Cancer Biorepository Faculty Advisory Committee. His lab maintains collaborations across immunology and cancer biology, focusing on translating epigenetic discoveries into novel therapeutic strategies for hematological malignancies and solid tumors.
The Shi Lab operates from the M. Bert Storey Research Building, utilizing core facilities including bioinformatics, flow cytometry, and immune monitoring to advance cancer research.
